There's a peculiar irony in successful weight loss. You restrict calories, the scale drops, you feel lighter , and then you notice your arms look thinner in a way you didn't intend. The fat came off, yes, but so did some of the muscle. This phenomenon, lean tissue loss during caloric restriction, is one of the more frustrating realities of metabolic remodelling. It happens even when protein intake is adequate, even when resistance training continues. The body, it seems, doesn't always distinguish between what you want to lose and what you'd prefer to keep.
Enter nicotinamide adenine dinucleotide, or NAD+ (a central redox cofactor in every living cell). Over the past decade, NAD+ has moved from biochemistry textbooks into the longevity supplement market, often framed as a molecule that declines with age and might, if replenished, slow certain aspects of cellular aging. The St. Petersburg Institute of Bioregulation and Gerontology has long emphasised the role of intracellular cofactors in maintaining tissue homeostasis, and NAD+ fits squarely within that framework. But can it actually preserve muscle mass when you're in a caloric deficit? Or is this another case of extrapolating from cell culture to human physiology with more hope than evidence?
The question matters because muscle loss during weight loss isn't trivial. Lose ten kilograms of body weight, and somewhere between 20 and 40 percent of that might come from lean tissue if you're not careful (Forbes 2000). That lean tissue carries your metabolic rate, your functional strength, your glucose disposal capacity. Lose too much, and you've traded one metabolic problem for another. So the idea that a molecule already circulating in your cells might shift the balance toward fat oxidation and away from muscle catabolism is, at minimum, worth examining.
What NAD+ Does, and Why It Might Matter for Muscle
NAD+ sits at the centre of energy metabolism. It accepts electrons during glycolysis and the citric acid cycle, ferrying them to the electron transport chain where ATP gets made. Without adequate NAD+, mitochondrial function falters. That's the textbook version. But NAD+ also acts as a substrate for enzymes called sirtuins (particularly SIRT1 and SIRT3), which regulate gene expression related to mitochondrial biogenesis, oxidative stress resistance, and protein turnover (Imai 2010). In skeletal muscle, SIRT1 activation has been linked to improved insulin sensitivity and reduced atrophy signalling, at least in rodent models.
The logic, then, is this: if NAD+ levels drop during aging or metabolic stress, sirtuin activity declines, mitochondrial quality deteriorates, and muscle becomes more susceptible to breakdown. Restore NAD+ , through supplementation with precursors like nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) , and you might reactivate those protective pathways. Except, and this matters, NAD+ doesn't cross cell membranes intact. You can't simply swallow NAD+ and expect it to flood your myocytes. You take a precursor, your cells convert it, and the resulting NAD+ pool may or may not reach the levels needed to shift sirtuin activity in a meaningful way.
Human data on NAD+ precursors and muscle preservation during weight loss is sparse. Most studies have focused on aging, insulin resistance, or endurance performance, not caloric restriction per se. A small trial in overweight adults given NR for twelve weeks showed improved insulin sensitivity but no significant change in lean mass (Dollerup 2018). Another study in older adults found that NMN supplementation increased muscle insulin sensitivity and modestly improved muscle function, but again, this wasn't in the context of intentional weight loss (Yoshino 2021). The muscle preservation question remains largely unanswered by direct human trials.
The Peptide Parallel: Epitalon and Tissue Maintenance
Within the bioregulator framework, there's a conceptual parallel worth noting. Epitalon (a tetrapeptide, Ala-Glu-Asp-Gly) has been studied primarily for its effects on the pineal gland and circadian regulation, but the St. Petersburg group has also documented its influence on tissue repair and protein synthesis across multiple organs (Khavinson 2003). The mechanism isn't identical to NAD+ , Epitalon appears to work through gene expression modulation rather than direct metabolic cofactor activity , but the outcome is similar: a shift in the cellular environment that favours maintenance over degradation.
Epitalon doesn't directly prevent muscle loss during caloric restriction, at least not in any published study I'm aware of. But it does seem to stabilise protein turnover and reduce markers of oxidative damage, which are both relevant when the body is under metabolic stress. The dose used in Russian research has typically been in the neighbourhood of 10 to 20 micrograms per day, administered subcutaneously, often in cycles rather than continuously. Whether combining Epitalon with NAD+ precursors would produce additive effects on lean tissue preservation is speculative, but not implausible. Both compounds influence the cellular machinery that decides whether to build, maintain, or break down tissue.
Other peptides in the bioregulator catalogue , Pinealon (for CNS support), Vesugen (vascular), Thymalin (immune) , don't have direct muscle-preservation data, but they reflect a broader principle: small molecules that fine-tune regulatory pathways can sometimes produce effects that blunt dosing of single nutrients cannot. NAD+ precursors fit into this category. They're not nutrients in the classical sense, but they're not drugs either. They're modulators.
Where the Evidence Ends
Here's what we don't know. We don't know if raising NAD+ levels by, say, 50 percent in human muscle tissue (assuming NR or NMN can do that reliably) translates into measurable differences in nitrogen balance during a caloric deficit. We don't know if the sirtuin activation seen in cell culture occurs at physiologically relevant intensities in whole humans eating 500 fewer calories per day. We don't know if there's a threshold dose below which NAD+ precursors do nothing for muscle preservation, or a ceiling above which more doesn't help.
We also don't know how NAD+ supplementation interacts with other variables that influence lean mass during weight loss: protein intake, resistance training volume, sleep quality, cortisol dynamics. It's possible that NAD+ precursors only matter when one of those other factors is suboptimal, acting as a buffer rather than a primary driver. Or maybe they don't matter at all for muscle preservation, and the benefits , if they exist , are confined to metabolic health markers like glucose tolerance and lipid oxidation.
This is general educational content. Personal health decisions should involve a qualified clinician familiar with your medical history.
The Russian bioregulator tradition has always been comfortable with this kind of uncertainty. You don't wait for a double-blind trial with 500 participants before you start thinking about how a molecule might fit into a broader strategy. You look at the mechanisms, you look at the safety profile, you consider the context, and you make a provisional decision. NAD+ precursors are generally well-tolerated, with doses of 250 to 1000 milligrams per day of NR or NMN producing few side effects in published trials. The cost is non-trivial but not prohibitive. The risk is low.
Implications for Practice
If you're losing weight and want to preserve as much muscle as possible, the first-line strategies remain unchanged: adequate protein (something like 1.6 to 2.2 grams per kilogram of body weight), progressive resistance training, and a moderate caloric deficit rather than an aggressive one. NAD+ precursors might add a marginal benefit on top of that foundation, particularly if you're older or metabolically compromised. They're unlikely to rescue a poorly designed diet or replace the stimulus of lifting heavy things.
The peptide angle , Epitalon, specifically , is harder to operationalise outside of research settings or clinical contexts where subcutaneous peptide administration is routine. But for those already working within that framework, a short cycle of Epitalon during a fat loss phase isn't unreasonable. The safety data from Russian trials is reassuring, and the theoretical basis for tissue protection is sound, even if the muscle-specific evidence is thin.
What's emerging, slowly, is a picture of NAD+ not as a magic bullet but as a metabolic tuning agent. It won't override thermodynamics. It won't prevent all lean tissue loss. But it might shift the ratio slightly in favour of fat oxidation, improve mitochondrial efficiency enough that muscle cells are less likely to be cannibalised for gluconeogenesis, and support the cellular repair processes that keep muscle functional even under metabolic stress. That's not nothing. It's just not everything.
Common questions
Does NAD+ supplementation directly prevent muscle loss during a caloric deficit?
There's no direct human trial showing that NAD+ precursors like NR or NMN prevent muscle loss during intentional weight loss. Mechanistically, NAD+ supports sirtuin activity and mitochondrial function, both of which could theoretically favour muscle preservation. But the evidence so far comes mostly from insulin sensitivity and aging studies, not caloric restriction contexts. It's plausible, not proven. If you're losing weight, prioritise protein intake and resistance training first; NAD+ precursors might add a marginal benefit but won't replace foundational strategies.
What dose of NAD+ precursors is used in research?
Most human trials have used doses between 250 and 1000 milligrams per day of nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). Some studies go higher, up to 2000 milligrams, but there's no clear dose-response relationship established yet for muscle outcomes. The Russian bioregulator tradition tends toward lower, more frequent dosing of related compounds, but NAD+ precursors are typically taken as single daily doses. Safety appears good across this range, though long-term data beyond twelve weeks is limited.
Can Epitalon and NAD+ precursors be used together?
Theoretically, yes. Epitalon works through gene expression modulation and circadian regulation, while NAD+ precursors act as metabolic cofactors. There's no obvious mechanistic conflict, and both have been used safely in separate contexts. The St. Petersburg Institute work suggests Epitalon is typically dosed at 10 to 20 micrograms per day subcutaneously, often in short cycles. Combining it with oral NAD+ precursors during a fat loss phase is speculative but not unreasonable. No published data exists on this specific combination, so anyone exploring it should proceed cautiously and ideally under clinical guidance.
What are the side effects of NAD+ supplementation?
NAD+ precursors like NR and NMN are generally well-tolerated. Some people report mild nausea or flushing at higher doses, likely related to the nicotinamide component. There's no evidence of serious adverse effects in trials lasting up to twelve weeks. Long-term safety data is still accumulating. Because NAD+ influences so many cellular processes, there's theoretical concern about effects on cancer cell metabolism, but no human data supports this worry. Standard practice is to start at a lower dose and assess tolerance before increasing.
Does NAD+ decline during weight loss?
NAD+ levels decline with age, and there's some evidence they drop during metabolic stress, but whether caloric restriction per se lowers NAD+ in human muscle isn't well-documented. Animal studies suggest fasting can actually increase NAD+ transiently through activation of salvage pathways. The concern isn't that dieting depletes NAD+ directly, but that lower NAD+ status (from aging or metabolic dysfunction) might make muscle more vulnerable to catabolism during energy restriction. Supplementing precursors could, in theory, buffer that vulnerability, but again, direct evidence is lacking.